Category Archives: Uncategorized

PMID:  J Cell Physiol. 2019 Aug ;234(10):17305-17313. Epub 2019 Feb 20. PMID: 30790283 Abstract Title:  In vitro and in vivo studies of antiosteosarcoma activities of formononetin. Abstract:  Osteogenic sarcoma (OGS) is a primary bone cancer, characterized by aggressive neoplasm from mesenchymal oncogenesis. However, the clinical therapeutic regimen against OGS is limited. Therefore, potential medication warrants …

Continue reading “In vitro and in vivo studies of antiosteosarcoma activities of formononetin.”

PMID:  J Cell Mol Med. 2019 May ;23(5):3505-3511. Epub 2019 Mar 15. PMID: 30873755 Abstract Title:  Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma: Findings of bioinformatic and experimental assays. Abstract:  In current study, a bioinformatic-based network pharmacology was used to identify the osteosarcoma (OGS)-pathological targets and formononetin (FN)-treated targets before the main core …

Continue reading “Anti-colorectal cancer mechanisms of formononetin identified by network pharmacological approach.”

PMID:  Mol Brain. 2019 04 8 ;12(1):36. Epub 2019 Apr 8. PMID: 30961625 Abstract Title:  Anxiolytic effects of Formononetin in an inflammatory pain mouse model. Abstract:  Chronic pain is commonly accompanied with anxiety disorder, which complicates treatment. In this study, we investigated the analgesic and anxiolytic effects of Formononetin (FMNT), an active component of traditional …

Continue reading “Anxiolytic effects of Formononetin in an inflammatory pain model.”

PMID:  CNS Neurol Disord Drug Targets. 2019 Aug 7. Epub 2019 Aug 7. PMID: 31389320 Abstract Title:  Formononetin ameliorates cognitive disorder via PGC-1α pathway in neuroinflammation conditions in high-fat diet-induced mice. Abstract:  Alzheimer's disease (AD) is one of the most common neurodegenerative diseases in many modern societies. Previous studies have shown that neuroinflammation is one …

Continue reading “Formononetin could improve the cognitive function by inhibiting neuroinflammation.”

PMID:  Biomolecules. 2019 Jul 7 ;9(7). Epub 2019 Jul 7. PMID: 31284669 Abstract Title:  Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model. Abstract:  Here, we determined the anti-neoplastic actions of formononetin (FT) against multiple myeloma (MM) and elucidated its possible mode of action. It was observed …

Continue reading “Formononetin regulates multiple oncogenic signalling cascades and enhances sensitivity to bortezomib in a multiple myeloma mouse model.”

PMID:  Front Pharmacol. 2019 ;10:820. Epub 2019 Jul 26. PMID: 31402861 Abstract Title:  Formononetin: A Review of Its Anticancer Potentials and Mechanisms. Abstract:  Cancer, a complex yet common disease, is caused by uncontrolled cell division and abnormal cell growth due to a variety of gene mutations. Seeking effective treatments for cancer is a major research …

Continue reading “A review of formononetin and its anticancer potentials and mechanisms.”

PMID:  Eur J Pharmacol. 2019 Oct 15 ;861:172619. Epub 2019 Aug 17. PMID: 31430458 Abstract Title:  Medical findings of nasopharyngeal carcinoma patients and anti-tumor benefits of formononetin. Abstract:  Epidemiologically, a malignancy of nasopharyngeal carcinoma (NPC) is endemic in worldwide, characterized with high invasiveness and lethality. Formononetin (FN), an anti-tumor bioactive component, is found to exert …

Continue reading “Medical findings of nasopharyngeal carcinoma patients and anti-tumor benefits of formononetin.”

PMID:  Oncol Lett. 2019 Sep ;18(3):2248-2253. Epub 2019 Jul 5. PMID: 31452725 Abstract Title:  Effects and significance of formononetin on expression levels of HIF-1α and VEGF in mouse cervical cancer tissue. Abstract:  Effects and significance of formononetin on the expression levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in mouse cervical cancer …

Continue reading “Formononetin can inhibit the growth of cervical cancer and reduce the mRNA and protein expression levels of HIF-1α and VEGF.”

PMID:  J Nutr Biochem. 2019 Jul 25 ;73:108214. Epub 2019 Jul 25. PMID: 31520816 Abstract Title:  Formononetin alleviates hepatic steatosis by facilitating TFEB-mediated lysosome biogenesis and lipophagy. Abstract:  Formononetin has been reported to ameliorate hyperlipidemia and obesity, but its effect and mechanism of action in anti-non-alcoholic fatty liver disease (NAFLD) remain unclear. Lipophagy is a …

Continue reading “Formononetin alleviates hepatic steatosis by facilitating TFEB-mediated lysosome biogenesis and lipophagy.”

PMID:  Mol Med Rep. 2019 Sep ;20(3):2893-2901. Epub 2019 Jul 19. PMID: 31524234 Abstract Title:  Formononetin ameliorates high glucose‑induced endothelial dysfunction by inhibiting the JAK/STAT signaling pathway. Abstract:  High glucose‑induced endothelial Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling is associated with the development and progression of the vascular complications of diabetes. The …

Continue reading “Formononetin ameliorates high glucose‑induced endothelial dysfunction.”